All News
Novel and Emerging Therapies in Psoriatic Arthritis
Recent advancements in targeted therapies, including selective inhibitors of key inflammatory pathways, offer promising outcomes for patients with active psoriatic arthritis (PsA). At ACR 2024, there have been further developments in novel therapies in PsA.
Read Article
Sex related differences in PsA
Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA).
Read Article
Up-front Secukinumab in PsA?
We now have an absolute plethora of agents available for use in psoriatic arthritis (PsA). In contrast we have an almost complete lack of understanding of how best to optimise use of these agents – what is the right agent at the right time for the right patient. A study presented this week has given us some further information on the topic.
Read Article
PsA Ultrasound Updates
Dr. Catherine Bakewell and Dr. Lihi Eder discuss updates on ultrasound in psoriatic arthritis at #ACR2024
https://t.co/XJOuKl8lCF https://t.co/XPMlf3sOnU
Dr. John Cush RheumNow ( View Tweet)
Sex related differences in PsA
Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA). Recently, there is new evidence that sex-related differences play a role not only in disease manifestations but also in efficacy and safety… https://t.co/9z9lorLtp0 https://t.co/XZRvm0S585
Dr. John Cush RheumNow ( View Tweet)
NEW ONLINE POSTER: Safety of a JAKi presented at EULAR 2024!
View safety across 15,000 patient-years of data from 11 Phase 3 trials, including adult patients with RA, PsA, AS, and nr-axSpA. This poster is sponsored by AbbVie US Medical Affairs.
https://t.co/gIFWRqOGmD https://t.co/L0YttKihdf
Dr. John Cush RheumNow ( View Tweet)
Up-front Secukinumab in PsA?
We now have an absolute plethora of agents available for use in psoriatic arthritis (PsA). In contrast we have an almost complete lack of understanding of how best to optimise use of these agents – what is the right agent at the right time for the… https://t.co/OAQOutluPe https://t.co/gLfG840DBP
Dr. John Cush RheumNow ( View Tweet)
RheumNow Day 2 Recap: #ACR24 Highlights
Catch the latest insights from the ACR Annual Meeting, where leading experts share groundbreaking research and clinical advances in rheumatology. Don’t miss our live coverage of key takeaways and trends shaping the future of patient care.… https://t.co/F3rZzOTiSJ https://t.co/t3wROMBe7D
Dr. John Cush RheumNow ( View Tweet)
PsA Potpourri
Dr. Arthur Kavanaugh reviewed highlights on adult and pediatric sessions on uveitis, as well as interesting abstracts, at #ACR24
https://t.co/jsCMKHBFMk https://t.co/roZOZT3Mqd
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Day 4 Recap: ACR Convergence 2024 Highlights https://t.co/WvQB7y0bkm
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR24 BEST Abstracts from Day 1
The RheumNow faculty have parked at the plenaries, trafficked the posters and have been finding the best the meeting offers on the first day.
https://t.co/FHu616Jpyq https://t.co/oKuRcGRRAZ
Dr. John Cush RheumNow ( View Tweet)
#Poorer responses to #Rx in
#Females vs #males
Sex hormone and pathway differences
explained
👇
Biological differences
F start worse in disease activity
F May have ⬇️ response to #Rx
Yr in Preview C Ritchlin
@lihi_eder’s PsA work quoted
ACR24 @RheumNow @ACRheum @ACRBest https://t.co/EWoCvzOLiL
Janet Pope Janetbirdope ( View Tweet)
What is the effect of cs/bDMARDs on weight in #PsA?
⬇️Weight loss seen with:
IL17i
IL23i
csDMARDs
⬆️Weight gain seen with:
TNFi
IL12/23i
Important to consider #comorbidity & #BMI in management decisions in PsA
Ab2639 #ACR24 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
A#2582 McInnes
Sonelokimab - IL17A,F nanobody
Prior P2 in PsO, HS
ARGO: P2 W24 RCT
Significant improv in ACR response
High PASI90/100 data
Up to 60% achieved MDA by W24
Improved PsAID domains (PRO)
Safety no IBD, MACE, depr. 2% oral candida
IZAR-1,2 - P3 ongoing
#ACR24 @RheumNow https://t.co/O4fEhTC8jK
Links:
Eric Dein ericdeinmd ( View Tweet)
SEC demonstrated high retention rates after 5 years in pts with PsA and r-axSpA in this real-world study.
Reasons for stopping SEC:
lack of efficacy
pt decision
lost to ffup
AEs
Reassuring data on SECs position in the treatment of PsA/AS.
@Rheumnow #ACR24 abs2344 https://t.co/zECEsheQIi
sheila RHEUMarampa ( View Tweet)
A#2583
Apremilast for axial inflamm in PsA, assess by CANDEN MRI scoring
MOSAIC P4 open label trial
Reduction in inflammation seen in vertebral bodies & posteriolateral, not in facet joints
No changes in SPARCC SIJ, spine - though low baseline SIJ inflammation
@RheumNow #ACR24 https://t.co/3GKEGJbtdc
Eric Dein ericdeinmd ( View Tweet)
A#2584 Mease
Zasocitinib TAK-279 - potent, selective TYK2i
P2b, 12w PsA RCT
15/30 mg - similar response, better than PBO for ACR20/50/70, MDA, DAPSA, PASDAS
29% MDA v 13% PBO
Safety no signal for MACE, cancer, serious ifn, death. Mild acne signal noted
@RheumNow #ACR24 https://t.co/1eqD9R5fLe
Links:
Eric Dein ericdeinmd ( View Tweet)
Selective TYK2i zasocitinib, results of Phase 2 DBRCT Dose dependent improvements in various PsA outcomes; NNT~5 for DAS28 remission, NNT~20 for PASDAS Hard to compare to current agents, somewhere between JAKs (woot!) & "apremlist zone" 🫣 #ACR24 @RheumNow Abstr#2584 #ACRbest https://t.co/t0y6C618ll
Mike Putman EBRheum ( View Tweet)
A#2585
PsABIOnd observ cohort study of IL23 (GUS) or IL17i
6 mo interim results of 686 pts
PROs: PsAID-12
High Rx persistence at 6mo -94% on both Rx
Comparable improvement in PsAID-12 - best results skin, discomfort
1/2 with clinically meaningful improvement
#ACR24 @RheumNow https://t.co/TM1jwTRR7C
Links:
Eric Dein ericdeinmd ( View Tweet)
A#2586
EBIO study - secukinumab on entheseal bx in PsA. Compare b/l to 3+ mo on SEC
Biopsy: change of entheseal cell composition on IL-17A Rx
- decr Il-17A producing cells in responding pts
Spatial transcriptomics - colocalizarjon of ILC2, CD200+ fibroblasts
@RheumNow #ACR24 https://t.co/kMiqpBRxuE
Eric Dein ericdeinmd ( View Tweet)
